Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

AFP464 in Treating Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: AFP464
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-08-29

Last Posted Date: 2013-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00369200

Locations: 🇺🇸
Wayne State University, Detroit, Michigan, United States

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Phase 2

Completed

Conditions: Oral Leukoplakia

Interventions: Drug: rosiglitazone maleate
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2013-02-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00369174

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Phase 1

Completed

Conditions: Stage IIIC Breast Cancer
Stage IIIB Breast Cancer
Male Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: vorinostat
Drug: paclitaxel
Biological: bevacizumab

First Posted Date: 2006-08-29

Last Posted Date: 2015-11-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00368875

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Recurrent Adult Brain Tumor
Adult Anaplastic Oligodendroglioma
Adult Gliosarcoma
Adult Anaplastic Astrocytoma

Interventions: Biological: ziv-aflibercept
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2015-10-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00369590

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 4 locations

Energy Homeostasis in Anorexia Nervosa

Completed

Conditions: Anorexia Nervosa

First Posted Date: 2006-08-25

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 120

Registration Number: NCT00368667

Locations: 🇺🇸
New York State Psychiatric Institute, Unit 98, New York, New York, United States

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Phase 2

Terminated

Conditions: Anaplastic Large Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: SGN-30

First Posted Date: 2006-08-17

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT00365274

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

Phase 2

Completed

Conditions: Tobacco Use Disorder
Healthy, no Evidence of Disease

Interventions: Other: laboratory biomarker analysis
Other: pharmacological study
Drug: curcumin

First Posted Date: 2006-08-17

Last Posted Date: 2015-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00365209

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

Phase 2

Completed

Conditions: Recurrent Adult Primary Liver Cancer
Advanced Adult Primary Liver Cancer
Adult Primary Hepatocellular Carcinoma
Localized Unresectable Adult Primary Liver Cancer

Interventions: Biological: bevacizumab
Drug: erlotinib hydrochloride

First Posted Date: 2006-08-17

Last Posted Date: 2015-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00365391

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Phase 1

Active, not recruiting

Conditions: Advanced Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Metastatic Urothelial Carcinoma
Recurrent Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Stage IV Bladder Urothelial Carcinoma AJCC v7
Unresectable Urothelial Carcinoma

Interventions: Drug: Eribulin Mesylate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2006-08-17

Last Posted Date: 2025-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 132

Registration Number: NCT00365157

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Community Howard Regional Health, Kokomo, Indiana, United States

and more 23 locations

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Epithelial Mesothelioma
Sarcomatous Mesothelioma
Recurrent Malignant Mesothelioma
Advanced Malignant Mesothelioma

Interventions: Drug: belinostat
Other: laboratory biomarker analysis

First Posted Date: 2006-08-17

Last Posted Date: 2018-06-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT00365053

Locations: 🇺🇸
City of Hope, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy